Clinical trial
A Study to Describe the Switching From a First- or Second-line Disease Modifying Therapy (DMT) to Ozanimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
Abstract
The purpose of this study is to describe the reasons, therapy, and/or disease for changing first or second line Disease Modifying Therapy (DMT) to ozanimod in participants with Relapsing Remitting Multiple Sclerosis (RRMS).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticlePsilocybin
Race and Gender Differences in the Moderating Relationship of Psychedelics on Stigma and Distress.
ArticleAyahuasca
Analysis of 28 hair samples from users of the hallucinogenic beverage ayahuasca.
ArticleAyahuasca